Spero Therapeutics Inc (STU:2HA) Stock Price, Trades & News

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Financial Strength

8/10

Name	Current	Vs Industry	Vs History
Cash-To-Debt	22.69
Equity-to-Asset	0.9
Debt-to-Equity	0.05
Debt-to-EBITDA	0.18
Interest Coverage	N/A	N/A	N/A
Piotroski F-Score	6/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	4.45	Distress Grey Safe
Beneish M-Score	-1.4	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

2/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	-7.9
	3-Year FCF Growth Rate	-1.3
	3-Year Book Growth Rate	-10.3

Momentum Rank

8/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	39.97
	9-Day RSI	38.93
	14-Day RSI	40.22
	3-1 Month Momentum %	16.36
	6-1 Month Momentum %	24.08
	12-1 Month Momentum %	1.12

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	10.5
	Quick Ratio	10.5
	Cash Ratio	10.23

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-2.5
	Shareholder Yield %	1.08

Profitability Rank

3/10

	Name	Current	Vs Industry		Vs History
	Operating Margin %	25.89
	Net Margin %	27.82
	EBITDA Margin %	25.89
	FCF Margin %	12.99
	OCF Margin %	12.99
	ROE %	37.14
	ROA %	23.66
	ROIC %	90.76
	3-Year ROIIC %	-2905.87
	ROC (Joel Greenblatt) %	720.67
	ROCE %	28.37
	Years of Profitability over Past 10-Year	2
	Moat Score	5
	Tariff Resilience Score	8

GF Value Rank

1/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	9.1
	Forward PE Ratio	4.08
	PE Ratio without NRI	8.71
	PS Ratio	2.58
	PB Ratio	2.39
	Price-to-Tangible-Book	2.41
	Price-to-Free-Cash-Flow	14.66
	Price-to-Operating-Cash-Flow	14.66
	EV-to-EBIT	5.14
	EV-to-EBITDA	5.14
	EV-to-Revenue	1.33
	EV-to-Forward-Revenue	1.52
	EV-to-FCF	10.06
	Price-to-GF-Value	2.09
	Price-to-Graham-Number	0.96
	Price-to-Net-Current-Asset-Value	2.44
	Price-to-Net-Cash	2.54
	Earnings Yield (Greenblatt) %	19.46
	FCF Yield %	5.72

Financials (Next Earnings Date:2026-08-12 Est.)

Annual Quarterly TTM

STU:2HA's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Spero Therapeutics Inc Executives

Details

GF Value™: €0.91

STU:2HA

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 2HA. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	46.92
	EPS (TTM) (€)	0.204
	Beta	0.8271
	3-Year Sharpe Ratio	0.4
	3-Year Sortino Ratio	2.46
	Volatility %	52.04
	14-Day RSI	40.22
	14-Day ATR (€)	0.129484
	20-Day SMA (€)	2.0982
	12-1 Month Momentum %	1.12
	52-Week Range (€)	1.538 - 2.604
	Shares Outstanding (Mil)	57.9

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	6
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Spero Therapeutics Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Spero Therapeutics Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings results for 2026	2026-11-13	In 133 days
Second quarter earnings conference call for 2026	2026-08-12 16:30	In 41 days
Second quarter earnings results for 2026	2026-08-12	In 40 days
General meeting for 2026	2026-06-23 09:00	1.91 (-1.65%)
First quarter earnings results for 2026	2026-05-13	2.14 (+1.32%)
Annual report for 2025	2026-03-27	2.10 (+2.44%)
Fourth quarter earnings results for 2025	2026-03-26	2.09 (+4.56%)
Third quarter earnings results for 2025	2025-11-13	2.33 (+4.97%)
Second quarter earnings conference call for 2025	2025-08-12 16:30	1.85 (+0.87%)
Second quarter earnings results for 2025	2025-08-12	1.85 (+0.87%)

Show

Entries

Spero Therapeutics Inc Frequently Asked Questions

What is Spero Therapeutics Inc(STU:2HA)'s stock price today?

The current price of STU:2HA is €1.90. The 52 week high of STU:2HA is €2.60 and 52 week low is €1.54.

When is next earnings date of Spero Therapeutics Inc(STU:2HA)?

The next earnings date of Spero Therapeutics Inc(STU:2HA) is 2026-08-12 Est..

Does Spero Therapeutics Inc(STU:2HA) pay dividends? If so, how much?

Spero Therapeutics Inc(STU:2HA) does not pay dividend.

Press Release

	Subject	Date
	Thinking about buying stock in CXApp, CCSC Technology International, Vroom, Spero Therapeutics, or OptiNose?	2024-03-14
	SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	2023-11-02
	SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors	2023-10-11
	SHAREHOLDER ALERT FILING DEADLINE TODAY: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - SPRO	2022-07-25
	Bronstein, Gewirtz & Grossman, LLC Reminds Spero Therapeutics, Inc. (SPRO) Shareholders of Class Action Deadline and Last Few Hours to Actively Participate	2022-07-25
	FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm	2022-07-25
	CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Spero Investors of a Lead Plaintiff Deadline of July 25, 2022	2022-07-25
	The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)	2022-07-22
	SPRO Investors Have Opportunity to Lead Spero Therapeutics, Inc. Securities Fraud Lawsuit	2022-07-15
	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 25, 2022 - (NASDAQ: SPRO)	2022-07-15

10/Page

Articles on Spero Therapeutics Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.